OSLO/LONDON, 30th May 2022: The Annual General Meeting of EXACT Therapeutics AS
("EXACT-Tx", Euronext Growth: EXTX), will be held as a virtual meeting at 10:30
CEST on 8th June 2022.
The notice of the Annual General Meeting with Attendance/Proxy forms, including
the Board of Directors' proposed resolutions for the items listed on the agenda
and the 2021 Annual Report are attached. The documents are also available at
www.exact-tx.com. The deadline for receiving proxies or attendance registration
is 6th June 2022 at 12:00 CEST.
For more information, please contact:
Masha Strømme, Executive Chair
Dominic Moreland, CFO
EXACT-Tx is a Norwegian clinical-stage precision health company developing a
technology platform for targeted therapeutic enhancement - Acoustic Cluster
Therapy (ACT®). ACT® is a proprietary formulation of microclusters (PS101)
activated by ultrasound for enhanced drug targeting deployed in multiple
indications to enhance the therapeutic efficacy of medicines through the use of
ultrasound-mediated drug delivery, for patients across multiple diseases.
Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.